EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants

Chung-Kuang Lu iD, Jrhau Lung iD, Li-Hsin Shu, Hung-Te Liu, Yu-Huei Wu, Yu-Shih Lin, Yao-Hsu Yang, Yu-Heng Wu, Ching-Yuan Wu

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25179498 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Chung-Kuang Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan. Hauptthemen laut MEDLINE: Catechin, Angiotensin-Converting Enzyme 2, Biflavonoids, SARS-CoV-2. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology (TW), Chang Gung Memorial Hospital (Chiayi).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing COVID-19 pandemic, caused by SARS-CoV-2, continues to pose significant global health challenges. The results demonstrated that GB-2 at 200 μg/mL effectively increased the population of 293T-ACE2 cells with low RBD binding for both SARS-CoV-2 Omicron EG.5.1 and HV.1 variants by dual-color flow cytometry, indicating its ability to inhibit virus attachment. Further investigation revealed that (+)-catechin at 25 and 50 μg/mL did not significantly alter the ACE2–RBD interaction for the EG.5.1 variant. In contrast, theaflavin showed inhibitory effects at both 25 and 50 μg/mL for EG.5.1, while only the higher concentration was effective for HV.1. Notably, theaflavin 3-gallate exhibited a potent inhibition of ACE2–RBD binding for both variants at both concentrations tested. Molecular docking studies provided insight into the binding mechanisms of theaflavin and theaflavin 3-gallate with the RBD of EG.5.1 and HV.1 variants. Both compounds showed favorable docking scores, with theaflavin 3-gallate demonstrating slightly lower scores (−8 kcal/mol) compared to theaflavin (−7 kcal/mol) for both variants. These results suggest stable interactions between the compounds and key residues in the RBD, potentially explaining their inhibitory effects on virus attachment. In conclusion, GB-2, theaflavin, and theaflavin 3-gallate demonstrate significant potential as inhibitors of the ACE2–RBD interaction in Omicron variants, highlighting their therapeutic promise against COVID-19. However, these findings are primarily based on computational and in vitro studies, necessitating further in vivo research and clinical trials to confirm their efficacy and safety in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CatechinAngiotensin-Converting Enzyme 2BiflavonoidsSARS-CoV-2Spike Glycoprotein, CoronavirusProtein BindingAntiviral AgentsHumansMolecular Docking SimulationHEK293 CellsCOVID-19COVID-19 Drug TreatmentVirus AttachmentEnterovirus B, HumanGallic Acid

Stichwörter der Autor:innen

GB-2SARS-CoV-2omicron variantsspike proteintheaflavintheaflavin 3-gallate

Substanzen

CatechinAngiotensin-Converting Enzyme 2BiflavonoidstheaflavinACE2 protein, humantheaflavine gallateSpike Glycoprotein, CoronavirusAntiviral Agentsspike protein, SARS-CoV-2Gallic Acid

Autor:innen und Institutionen

  • Department of Chinese Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
  • Department of Research and Development, Chiayi Chang Gung Memorial Hospital, Chiayi Branch, Putzu 613, Taiwan.
  • Department of Pharmacy, Chiayi Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
  • School of Chinese medicine, College of Medicine, Chang Gung University, Taoyuan 333, Taiwan.
  • Health Information and Epidemiology Laboratory, Chang Gung Memorial Hospital, Chiayi 613, Taiwan.
  • Institute of Communications Engineering, The National Yang Ming Chiao Tung University, Hsinchu City 30010, Taiwan.

ORCID-Profile: Chung-Kuang Lu, Jrhau Lung

Förderung

  • Ministry of Science and Technology (TW)
  • Chang Gung Memorial Hospital (Chiayi)

Zitieren

APA

Lu, C. K., Lung, J., Shu, L. H., Liu, H. T., Wu, Y. H., Lin, Y. S., Yang, Y. H., Wu, Y. H., & Wu, C. Y. (2024). The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179498

Vancouver

Lu CK, Lung J, Shu LH, Liu HT, Wu YH, Lin YS, et al. The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179498

BibTeX
@article{Lu2024,
  author = {Lu, Chung-Kuang and Lung, Jrhau and Shu, Li-Hsin and Liu, Hung-Te and Wu, Yu-Huei and Lin, Yu-Shih and Yang, Yao-Hsu and Wu, Yu-Heng and Wu, Ching-Yuan},
  title = {The Inhibiting Effect of GB-2, (+)-Catechin, Theaflavin, and Theaflavin 3-Gallate on Interaction between ACE2 and SARS-CoV-2 EG.5.1 and HV.1 Variants},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25179498}
}
Kostenlos starten →